Is NEO a Good Stock to Buy? The Bull and Bear Case (2026)
Last updated November 2026
Short answer
Both cases are real, which is why the question is contested. The bull case for NeoGenomics (NEO) rests on Mix shift into NGS carries the revenue line: Next-generation sequencing revenue grew roughly 26% year over year in the second quarter of 2026 while total clinical volume rose about 2%. The bear case rests on gAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $52 million and no positive price-to-earnings ratio to anchor valuation. Analysts covering it publish targets from $19.00 to $35.00 against a $15.41 share price on November 16, 2026, so even the professionals disagree by 68% of their own average. We do not give a verdict. Each case is set out below at full strength, so you can decide which set of assumptions you actually believe. Walnut is not an investment adviser.
NEO key stats
At $15.41 on November 16, 2026, NeoGenomics (NEO) has a market cap of $2.0B.
- Market cap
- $2.0B
- P/E (forward)
- 49.0
- Price to book
- 2.5
- Beta
- 1.83
Market cap, P/E and yield are measured at the $15.41 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.
What's new with NeoGenomics (NEO)?
The last two weeks for NeoGenomics, as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.
- NEO closed at $15.41 on November 16, 2026, down 12.4% over the past five trading days (from $17.60).
NeoGenomics filed no current, quarterly or annual report with the SEC in the last two weeks.
Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.
NeoGenomics, Inc. (Nasdaq: NEO) operates a national network of CLIA-certified, CAP-accredited laboratories that perform cancer genetics testing, plus a full-service sample-processing lab in Cambridge, United Kingdom. Its customers are community oncology and pathology practices, hospital pathology labs, academic centers and pharmaceutical companies, and its menu spans older modalities such as FISH, IHC and PCR alongside next-generation sequencing panels and molecular residual disease testing through the RaDaR franchise. Management reports the company as a single segment with roughly 2,500 employees, and clinical testing supplies the large majority of revenue, with pharma and advanced diagnostics work making up the smaller remainder. Anthony (Tony) Zook took over as chief executive and has been reorganizing the commercial effort, including a dedicated pathology and oncology sales team launched during 2026. On October 5, 2026 the company announced that president and chief operating officer Warren Stone will succeed Zook as CEO on January 4, 2027, with Zook becoming executive chair and board chair Lynn Tetrault stepping down from that role the same day. In mid-October it also expanded its Indica Labs partnership to scale AI-powered digital pathology. What makes the stock interesting is arithmetic that has quietly changed shape. Second-quarter 2026 revenue of about $202 million grew roughly 11% year over year, but clinical test volume rose only about 2%; average revenue per clinical test climbed roughly 12% to about $515 as NGS revenue grew about 26%. Adjusted gross margin expanded about 260 basis points, adjusted EBITDA rose about 36% to roughly $14 million, and management raised full-year 2026 guidance to roughly $802 million to $806 million of revenue with adjusted EBITDA of roughly $56 million to $58 million. GAAP profitability remains absent, with a trailing twelve-month net loss near $52 million, and the balance sheet now carries about $385 million of convertible principal against roughly $146 million of cash and short-term investments after a June 2026 refinancing. The same October announcement put preliminary third-quarter revenue at about $209 million, above a consensus near $205.9 million, with NGS revenue up about 28%, yet full-year guidance was only reiterated, which implies a fourth quarter no larger than the third. The shares dropped about 12% that day and have fallen about 16% over the past month, though they remain up about 42% for 2026. Anyone weighing NEO is essentially asking whether the price and mix tailwind can continue long enough to close that gap.
The bull case: what would have to be true for $35.00
The most optimistic published target on NEO is $35.00, +127.1% from the $15.41 share price on November 16, 2026. Getting there needs the following to work close to its best case, not merely to avoid going wrong.
1. Mix shift into NGS carries the revenue line
Next-generation sequencing revenue grew roughly 26% year over year in the second quarter of 2026 while total clinical volume rose about 2%. Each NGS panel replaces cheaper legacy testing at a materially higher price, which lifted average revenue per clinical test to roughly $515 from about $461 a year earlier. Continued menu migration is the single largest swing factor in whether the company hits the upper end of its guidance. Preliminary third-quarter figures released October 5, 2026 showed NGS revenue up about 28%, so the trend held into the second half.
2. Margin discipline turning into real adjusted EBITDA
Adjusted gross margin reached roughly 48% in the second quarter, an expansion of about 260 basis points, and operating expenses fell roughly 19% against a year-ago quarter that carried about $20 million of impairment charges. Adjusted EBITDA guidance of roughly $56 million to $58 million for 2026 would represent growth of about 29% to 34% over the $43 million recorded in 2025. Whether that flows through to GAAP profitability depends on amortization of acquired intangibles and stock-based compensation, both of which remain sizeable.
3. RaDaR and molecular residual disease reimbursement
The company submitted new RaDaR ST evidence to MolDx during the quarter, its third submission awaiting a Medicare coverage decision for an additional indication. MRD testing is recurring by design, since patients are monitored repeatedly after treatment, so approved indications compound rather than deliver a one-time bump. Coverage decisions here are outside management control and their timing is genuinely uncertain.
4. A cleaner balance sheet and a resolved government matter
June 2026 brought a $316.3 million offering of 0.75% convertible senior notes due 2032, used partly to repurchase about $276 million of the 0.25% notes due 2028 and to buy back roughly $25 million of stock at $10.49 per share. That pushed the bulk of the maturity wall out to 2032 and produced an $11 million gain on debt extinguishment. Separately, a July 2026 civil settlement with the Department of Justice closed a self-disclosed consulting matter for $10.0 million without a corporate integrity agreement.
5. A planned CEO handoff
Warren Stone, the current president and chief operating officer, becomes chief executive on January 4, 2027, with Tony Zook moving to executive chair. Management framed it as a planned transition emphasizing strategic continuity, and analysts were mixed on the reaction: BTIG upgraded the stock to Buy with a $28 target and Needham raised its target to $22, while the shares fell about 12% on the day. Continuity of the commercial reorganization and the NGS push through the handoff is what to watch.
The bear case: what would have to be true for $19.00
The most pessimistic published target is $19.00, +23.3% from the current price. It is neither a floor nor a forecast; it is roughly what one analyst thinks NeoGenomics is worth if the risks below bite instead of the drivers above.
GAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $52 million and no positive price-to-earnings ratio to anchor valuation. Reimbursement concentration is the structural exposure: Medicare through MolDx and commercial payors set the prices behind that rising revenue-per-test figure, and evolving regulation of laboratory developed tests could raise the compliance cost of the same menu. Growth is currently priced rather than volume driven, since clinical test count rose only about 2% year over year, so any payor pushback on pricing would hit revenue quickly. On litigation, a purported securities class action captioned Goldenberg v. NeoGenomics (S.D.N.Y., No. 22-cv-10314, filed December 16, 2022, covering purchases between February 27, 2020 and April 26, 2022) was dismissed with prejudice on March 13, 2026, and the plaintiff appealed to the Second Circuit on April 10, 2026; related shareholder derivative actions in Nevada, Florida and New York remain stayed pending that appeal, and the company states the outcome is not currently estimable. Finally, goodwill and intangibles of roughly $795 million sit on a $1.35 billion balance sheet alongside about $385 million of convertible principal, and the 2025 InVisionFirst-Lung write-down showed that impairment of acquired assets is a live possibility. Leadership transition is a newer risk: a change of CEO in January 2027 can disrupt sales execution, and the stock already trades around 49 times forward EPS estimates, so the valuation leaves little room for a stumble, as the 12% one-day drop in October 2026 showed.
The bear case deserves the same attention as the bull case, and usually gets less. If you are holding NEO already, these risks exist either way; what to check is whether any of them has moved from possible to actually happening in the reported numbers.
Where analysts land on NEO
10 analysts cover NEO, with an average target of $23.40 (+51.8% against $15.41) and a split of 8 buy, 3 hold, 0 sell. Bear in mind sell-side ratings skew positive across the whole market, so that split is not a balanced vote. The full target table, the recent rating actions by firm, and how the consensus has shifted are on the NEO forecast and price target page.
How is NEO valued?
Market cap, P/E and dividend yield at today's price are in the NEO key stats above. The business figures below come from NeoGenomics's reported results as of October 2026 and change when it next reports.
- Revenue (TTM): ~$766M (four quarters ended June 30, 2026), up ~11% year over year in the latest quarter
- Q3 2026 revenue (preliminary): ~$209M vs ~$205.9M consensus; NGS revenue up ~28%
- Margins: Gross ~44%, operating ~-5%, net ~-7% (trailing)
- GAAP result: TTM net loss ~$52M; Q2 2026 net income ~$2M including an ~$11M debt extinguishment gain
- FY2026 guidance: Revenue ~$802M to ~$806M (reiterated October 2026); adjusted EBITDA ~$56M to ~$58M
- Next earnings: October 28, 2026; consensus EPS ~$0.06 on ~$207M revenue
As of October 2026: With no trailing GAAP earnings, sales and adjusted EBITDA multiples do most of the work here: roughly 2.8 times trailing revenue, about 49 times forward EPS estimates, and roughly 40 times the midpoint of guided 2026 adjusted EBITDA, which only looks reasonable if margin expansion continues for several more years. Balance sheet context matters too, since cash and short-term investments of about $146 million sit against roughly $385 million of convertible principal ($69.0M of 0.25% notes due 2028 and $316.3M of 0.75% notes due 2032), and the shares have ranged from about $7.07 to $20.15 over the past 52 weeks. The 10 analysts Yahoo tracks average a target near $21.85; figures are approximate as of October 16, 2026.
How do you decide if NEO is a buy?
Whether NEO is a buy is easier to judge through four narrower questions:
- Thesis: do you believe the bull case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold NEO indirectly through an index or sector ETF before adding more.
What would change your mind on NEO
Write the tripwires down before you need them. Deciding what would falsify your view is far harder once a position is moving against you.
- Bull case breaks if: Mix shift into NGS carries the revenue line stalls in the reported numbers. A shift in the narrative around them is not enough on its own.
- Bear case breaks if: gAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $52 million and no positive price-to-earnings ratio to anchor valuation fails to materialise over several reporting periods while the drivers keep compounding.
- Neither matters if: the position has grown large enough that being wrong would damage the whole portfolio. Sizing overrides the argument.
For the full picture, see the NEO stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about NEO against your real portfolio and see your actual exposure before deciding.
Your questions about NeoGenomics
Ask Walnut's AI anything about NEO and see how it fits what you own.
FAQ
Is NEO a good stock to buy right now?
+
That depends on which case you find more convincing, and both are on this page. The bull case rests on Mix shift into NGS carries the revenue line, with revenue (ttm) at ~$766M (four quarters ended June 30, 2026), up ~11% year over year in the latest quarter. The bear case rests on gAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $52 million and no positive price-to-earnings ratio to anchor valuation. Analysts covering it are spread from $19.00 to $35.00, a spread wide enough to show the question is contested. If you believe the thesis, the questions that matter next are sizing and overlap; timing comes after. Walnut is not an investment adviser and this is not a recommendation.
Should I sell NEO?
+
Nobody can answer that for you, and a more useful version of the question is narrower: has anything changed in the reason you bought it? The bear case on this page is the place to check. GAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $52 million and no positive price-to-earnings ratio to anchor valuation. If that risk is what you were worried about and it is now playing out, take it seriously. If the price simply fell while the thesis held, the situation is different. The most pessimistic published target is $19.00, +23.3% from the $15.41 price, which is one analyst's downside case. It is not a floor. Walnut is not an investment adviser.
What is the bull case for NEO?
+
Mix shift into NGS carries the revenue line. Next-generation sequencing revenue grew roughly 26% year over year in the second quarter of 2026 while total clinical volume rose about 2%. The most optimistic analyst target on NEO is $35.00, +127.1% from the $15.41 price. That figure is only reachable if this thesis works close to its best case.
What is the bear case for NEO?
+
GAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $52 million and no positive price-to-earnings ratio to anchor valuation. Reimbursement concentration is the structural exposure: Medicare through MolDx and commercial payors set the prices behind that rising revenue-per-test figure, and evolving regulation of laboratory developed tests could raise the compliance cost of the same menu. Growth is currently priced rather than volume driven, since clinical test count rose only about 2% year over year, so any payor pushback on pricing would hit revenue quickly. On litigation, a purported securities class action captioned Goldenberg v. NeoGenomics (S.D.N.Y., No. 22-cv-10314, filed December 16, 2022, covering purchases between February 27, 2020 and April 26, 2022) was dismissed with prejudice on March 13, 2026, and the plaintiff appealed to the Second Circuit on April 10, 2026; related shareholder derivative actions in Nevada, Florida and New York remain stayed pending that appeal, and the company states the outcome is not currently estimable. Finally, goodwill and intangibles of roughly $795 million sit on a $1.35 billion balance sheet alongside about $385 million of convertible principal, and the 2025 InVisionFirst-Lung write-down showed that impairment of acquired assets is a live possibility. Leadership transition is a newer risk: a change of CEO in January 2027 can disrupt sales execution, and the stock already trades around 49 times forward EPS estimates, so the valuation leaves little room for a stumble, as the 12% one-day drop in October 2026 showed. The most pessimistic published target is $19.00, +23.3% from the current price, which is roughly what one analyst thinks the stock is worth if these risks bite and the drivers do not.
What does NeoGenomics do?
+
NeoGenomics runs a specialised oncology testing laboratory network serving pathologists, oncologists and pharmaceutical partners.
What would have to change for NEO to stop being worth holding?
+
Decide that in advance, because it is far harder to think clearly once a position is moving against you. The concrete tripwires here: the driver behind the bull case (Mix shift into NGS carries the revenue line) stalling in the reported numbers (a change in the narrative alone does not count), the risk above (gAAP losses persist despite the improving adjusted figures, with a trailing twelve-month net loss near $52 million and no positive price-to-earnings ratio to anchor valuation) turning from a possibility into a reported fact, or the position growing large enough that a bad outcome would matter to your whole portfolio regardless of who is right.
What does NeoGenomics actually do?
+
It runs cancer diagnostic tests. Oncologists and pathologists send tumor tissue or blood samples to its CLIA-certified, CAP-accredited labs, which perform FISH, IHC, PCR and next-generation sequencing to identify the genetic characteristics of a cancer. Pharmaceutical companies also pay it for clinical trial testing and oncology data services.
Is NeoGenomics profitable?
+
Not on a GAAP basis. The trailing twelve-month net loss is roughly $52 million, and full-year 2026 guidance calls for a net loss of about $34 million to $42 million. Second-quarter 2026 did show GAAP net income of about $2 million, though that included an $11 million gain on debt extinguishment rather than operating improvement alone. On an adjusted basis it has beaten EPS estimates in each of its last four quarters, posting $0.05 against $0.03 in the June quarter.
How large is NeoGenomics and what is the stock worth?
+
Trailing twelve-month revenue is about $766 million and the market capitalization is roughly $2.2 billion, or about $16.73 per share as of October 16, 2026. That works out to roughly 2.8 times trailing sales, with about $146 million of cash against roughly $385 million of convertible principal.
Walnut is informational, not investment advice, and gives no verdict on NEO. Analyst targets referenced here come from a November 2026 pull of published third-party research and change constantly. The share price is the last one Yahoo Finance reported on November 16, 2026. Verify current figures with your broker before acting on them.